Echoes of the type of thinking surrounding the delay in Novartis ratifying the ARDS deal they had signed:
that was because...
1. they wanted to renegotiate a higher price
2. they wanted to license congestive heart failure treatment
3. they wanted to buy Mesoblast
Cell Therapy News/Articles, page-13475
-
- There are more pages in this discussion • 4,384 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.040(4.52%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 95.0¢ | 88.0¢ | $3.552M | 3.861M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 55067 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 161746 | 20 |
View Market Depth
| Last trade - 13.53pm 06/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |